Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05521997 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

Name: Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer — clinical trial record (NCT05521997)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorWashington University School of Medicine

Started2026-12-31

View on ClinicalTrials.gov ↗

Advanced cervical cancer patients treated with standard of care (SOC) chemoradiation plus glutaminase inhibition with telaglenastat (CB-839) will have increased progression-free survival (PFS) compared to historical rates for patients receiving SOC chemoradiation alone.

Amendment history 2 changes detected by DataLookout

2026-09-04

Primary completion pushed: 2032-10-07 → 2033-03-07

2026-09-04

Completion pushed: 2032-10-07 → 2033-03-07

Trial Details

NCT Number	NCT05521997
Lead Sponsor	Washington University School of Medicine Collaborators: National Cancer Institute (NCI), Calithera Biosciences, Inc
Conditions	Advanced Cervical Carcinoma, Cervical Cancer, Cervix Cancer, Cancer of the Cervix
Enrollment	42 participants
Start Date	2026-12-31
Primary Completion	2033-03-07 (estimated)
Study Completion	2033-03-07 (estimated)
Updated on ClinicalTrials.gov	2026-09-03